R Consortium R Submission Pilot 1 - Summary Tables and Figures

Note: In this pilot, different open-source packages were used when generating each of the 4 analysis outputs to test wider use case scenarios. The outputs were formatted differently intentionally to cover different company specific formatting choices.

Table 14-2.01

Summary of Demographic and Baseline Characteristics

```
Protocol: CDISCPILOT01
Population: Intent-to-Treat

-------------------------------------------------------------------------------
                                   Placebo      Xanomeline Low Dose  Xanomeline High Dose
                                   (N=86)             (N=84)               (N=84)
-------------------------------------------------------------------------------
Age
  Mean (sd)                      75.21 (8.59)      75.67 (8.29)         74.38 (7.89)
  Median                             76               77.5                  76
  Min - Max                        52 - 89           51 - 88             56 - 88
Pooled Age Group 1
  <65                                14                 8                   11
  65-80                              42                47                   55
  >80                                30                29                   18
Race
  WHITE                              78                78                   74
  BLACK OR AFRICAN AMERICAN           8                 6                    9
  AMERICAN INDIAN OR ALASKA NATIVE    0                 0                    1
Baseline Height (cm)
  Mean (sd)                     162.57 (11.52)    163.43 (10.42)       165.82 (10.13)
  Median                           162.6             162.6                165.1
  Min - Max                     137.2 - 185.4     135.9 - 195.6        146.1 - 190.5
Baseline Weight (kg)
  Mean (sd)                      62.76 (12.77)     67.28 (14.12)         70 (14.65)
  Median                           60.55             64.9                 69.2
  Min - Max                       34 - 86.2        45.4 - 106.1         41.7 - 108
Baseline BMI (kg/m^2)
  Mean (sd)                      23.64 (3.67)      25.06 (4.27)         25.35 (4.16)
  Median                            23.4             24.3                 24.8
  Min - Max                      15.1 - 33.3       17.7 - 40.1          13.7 - 34.5
MMSE Total
  Mean (sd)                      18.05 (4.27)      17.87 (4.22)         18.51 (4.16)
  Median                            19.5              18                   20
  Min - Max                       10 - 23           10 - 24             10 - 24
-------------------------------------------------------------------------------

Program: tlf_demographic.Rmd
2022-02-01 17:21:29
```

Table 14-3.01

Primary Endpoint Analysis: ADAS Cog (11) - Change from Baseline to Week 24 - LOCF

Population: Efficacy

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Baseline			
n	79	81	74
Mean (SD)	24.1 (12.19)	24.4 (12.92)	21.3 (11.74)
Median (Range)	21.0 (5;61)	21.0 (5;57)	18.0 (3;57)
Week 24			
n	79	81	74
Mean (SD)	26.7 (13.79)	26.4 (13.18)	22.8 (12.48)
Median (Range)	24.0 (5;62)	25.0 (6;62)	20.0 (3;62)
Change from Baseline			
n	79	81	74
Mean (SD)	2.5 (5.80)	2.0 (5.55)	1.5 (4.26)
Median (Range)	2.0 (-11;16)	2.0 (-11;17)	1.0 (-7;13)
p-value(Dose Response) [1][2]			0.245
p-value(Xan - Placebo) [1][3]		0.569	0.233
Diff of LS Means (SE)		-0.5 (0.82)	-1.0 (0.84)
95% CI		(-2.1;1.1)	(-2.7;0.7)
p-value(Xan High - Xan Low) [1][3]			0.520
Diff of LS Means (SE)			-0.5 (0.84)
95% CI			(-2.2;1.1)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Table 14-3.02

Primary Endpoint Analysis: Glucose (mmol/L) - Summary at Week 20 - LOCF

ANCOVA of Change from Baseline at Week 20

| Treatment	Baseline[a]		Week 20		Change from Baseline		
	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	LS Mean (95% CI)[b]
Xanomeline High Dose	84	5.4 (1.34)	31	5.8 (1.61)	31	0.2 (1.47)	0.16 (-0.31, 0.63)
Placebo	86	5.6 (2.14)	65	5.8 (1.50)	65	0.1 (2.08)	0.09 (-0.23, 0.42)
Pairwise Comparison	Difference in LS Mean (95% CI)[b]						p-Value
Xanomeline High Dose vs. Placebo	0.07 (-0.50, 0.63)						0.822
Root Mean Squared Error of Change = 1.30							
[a] Table is based on participants who have observable data at Baseline and Week 20. [b] Based on an Analysis of covariance (ANCOVA) model with treatment and baseline value as covariates CI = Confidence Interval, LS = Least Squares, SD = Standard Deviation							

Source: [pilot1wrappers: adam-adsl; adlbc]

Figure 14-1

Time to Dermatologic Event by Treatment Group

KM plot for Time to First Dermatologic Event: Safety population

At risk

Placebo	86	75	65	59	50	47	45	42	40	35	0
Xanomeline Low Dose	84	58	31	20	14	12	8	6	6	5	0
Xanomeline High Dose	84	48	31	14	7	4	4	4	4	3	0

Program: tlf_kmplot.Rmd [2022−02−01 17:21:39]